Ranbaxy Laboratories’ (RLL) - wholly owned subsidiary - Ranbaxy Pharmaceuticals Canada Inc. (RPCI), has received approval from Health Canada to manufacture and market RAN-Rosuvastatin tablets to the Canadian healthcare system.
Rosuvastatin is a HMG-COA Reductase Inhibitor, a cholesterol-lowering medication. The brand sales of Crestor in Canada were $742.2 million ($CAD-IMS-CDH: January, 2012). The finished dosage form was developed, and will be manufactured within RLL's Health Canada approved facilities located in India. The company anticipates making Rosuvastatin tablets available to all classes of trade after April 2 when sufficient supplies will be available to meet market demand.
RPCI is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system.
Ranbaxy Laboratories, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
